Beam Therapeutics Inc

Beam Therapeutics Inc Stock Forecast & Price Prediction

Live Beam Therapeutics Inc Stock (BEAM) Price
$33.54

7

Ratings

  • Buy 5
  • Hold 2
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$33.54

P/E Ratio

-8.12

Volume Traded Today

$1.2M

Dividend

Dividends not available for BEAM

52 Week High/low

41.44/16.95

Beam Therapeutics Inc Market Cap

$2.59B

🛑 Alert: These ten stocks could have higher potential than $BEAM 🛑

Before you buy BEAM you’ll want to see this list of ten stocks that have huge potential. Want to see if BEAM made the cut? Enter your email below

BEAM Summary

From what 7 stock analysts predict, the share price for Beam Therapeutics Inc (BEAM) might increase by 62.28% in the next year. This is based on a 12-month average estimation for BEAM. Price targets go from $30.00 to $78.00. The majority of stock analysts believe BEAM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

BEAM Analyst Ratings

About 7 Wall Street analysts have assigned BEAM 5 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Beam Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BEAM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

BEAM stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

eric joseph
J.P. Morgan

Buy

$40.0

upgraded

Jan 29, 2024
dae gon ha
Stifel Nicolaus

Buy

$66.0

maintained

Jan 15, 2024
kostas biliouris
BMO Capital

Buy

$57.0

maintained

Jan 9, 2024
sami corwin
William Blair

Buy

None

maintained

Jan 9, 2024
yanan zhu
Wells Fargo

Buy

$75.0

maintained

Jan 8, 2024
debjit chattopadhyay
Guggenheim

Buy

$78.0

maintained

Dec 21, 2023
greg harrison
Bank of America Securities

Hold

$35.0

downgraded

Dec 15, 2023
michael yee
Jefferies

Hold

$30.0

downgraded

Dec 8, 2023
samantha semenkow
Citi

Buy

$56.0

maintained

Nov 13, 2023
gena wang
Barclays

Hold

$26.0

maintained

Nov 8, 2023
luca issi
RBC Capital

Hold

$27.0

maintained

Nov 8, 2023
mani foroohar
Leerink Partners

Hold

$19.0

reiterated

Nov 8, 2023
rick bienkowski
Cantor Fitzgerald

Hold

None

downgraded

Oct 20, 2023
david nierengarten
Wedbush

Buy

$48.0

maintained

Oct 19, 2023
william pickering
Bernstein

Hold

$35.0

maintained

Aug 15, 2023
richard law cfa
Credit Suisse

Hold

$47.0

maintained

Aug 9, 2023
patrick b donnelly
Citigroup

Buy

$62.0

maintained

Mar 1, 2023
raju prasad
William Blair

Buy

None

initiatedcoverage

Feb 28, 2023
benjamin burnett
Stifel Nicolaus

Buy

$103.0

maintained

Nov 7, 2022

BEAM Company Information

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM
Beam Therapeutics Inc (BEAM)

When did it IPO

2020

Staff Count

439

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. John M. Evans M.B.A.

Market Cap

$2.59B

Beam Therapeutics Inc (BEAM) Financial Data

In 2023, BEAM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BEAM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $81.6M
  • Operating Margin TTM -629.7%
  • Gross profit TTM $0
  • Return on assets TTM -18.9%
  • Return on equity TTM -38.1%
  • Profit Margin 0.0%
  • Book Value Per Share 10.09%
  • Market capitalisation $2.59B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-4.17
... ...

Similar Stocks to Beam Therapeutics Inc - BEAM

🛑 Alert: These ten stocks could have higher potential than $BEAM 🛑

Before you buy BEAM you’ll want to see this list of ten stocks that have huge potential. Want to see if BEAM made the cut? Enter your email below

...

BEAM Frequently asked questions

The highest forecasted price for BEAM is $78.00 from debjit chattopadhyay at Guggenheim.

The lowest forecasted price for BEAM is $30.00 from michael yee from Jefferies

The BEAM analyst ratings consensus are 5 buy ratings, 2 hold ratings, and 0 sell ratings.